$26m funding injection for cardiovascular and cancer research

The University of Sydney has been awarded more than $26m for critical research into cardiovascular disease, brain cancer, autism, and to trial a vaccine for zoonotic disease, Q fever.

The funding, all announced in June, was awarded under several schemes of the Australian Government’s Medical Research Future Fund and the New South Wales Government’s Cardiovascular Research Capacity Program.

Sydney academics were also awarded $12.4m for stroke and heart disease research earlier in June and $62m for 43 medical research projects, including transforming the treatment of osteoarthritis, in late May.

Deputy Vice-Chancellor (Research) Professor Duncan Ivison said the funding success highlighted the University’s enduring strength in medical research, with more than half of the awarded cardiovascular grants going to Sydney academics.

Cardiovascular diseases are the leading cause of death globally. I’m proud that Sydney has some of the best researchers in Australia, and the world, working not only to understand the biology of these diseases, but to develop exciting new treatments using precision medicine, gene therapy, and biomedical devices.

Professor Duncan Ivison, Deputy Vice-Chancellor (Research)

The University is ranked first in Australia and 7th in the world for oncology (US News rankings 2019) and second in Australia and 18th in the world for medicine (QS Subject rankings 2020).

Fast-tracking safer implants

Associate Professor Steven Wise (pictured right) is leading a team of bioengineers, biologists, physicists and surgeons to establish a new centre to test the safety and efficacy of new cardiovascular implants, such as stents.

Current implants are typically made from metal alloys, such as stainless steel, or hydrophobic plastics, which are used to make Gore-Tex (rain jackets) or PET (water bottles).

Professor Wise says these materials are chosen for their durability and ease of mass manufacture, however, they promote blood clots, drive chronic inflammation, and commonly fail when inserted into the heart and legs.

“Metal stents have serious shortcomings when deployed in the legs and we urgently need alternatives. Many researchers, including those at Sydney, are working on new biomaterials that have the potential to revolutionise the treatment of cardiovascular disease.”

“Our new centre aims to test these new devices to ensure they are safe and effective. This is the first centre of its kind in New South Wales and we hope that it will mean Australians have quicker access to new and better technologies for the treatment of cardiovascular diseases.”

World-first trial of Q fever vaccine for young people

Associate Professor Nicholas Wood (pictured above) will lead a team to conduct the first clinical trial of a vaccine for Q fever in young people.

Q fever is a bacterial infection found in cattle, sheep, and goats. However, like other zoonotic diseases, such as COVID-19, it can jump to humans. Symptoms can be mild and flu-like, however serious cases can lead to a weakened immune system, with increased risk of other infections such as hepatitis, and damage to the heart, liver, brain and lungs.

Professor Wood, who is affiliaed with the National Centre for Immunisation Research and Surveillance, says the disease is highly preventable, with a vaccine produced in Australia and made available for those aged 15 years and older since 1989. However, young people are currently excluded from being inoculated.

“Adolescents with Q fever are at increased risk of developing persistent bone infections, which are very difficult to treat,” Professor Wood said.

“Our aim is to conduct the first prospective, multi-centre study which will systemically and comprehensively measure the safety of the Q fever vaccine for young people aged 10-15 years.”

“If the results show the vaccine is safe and effective in young people, it will lead to a change in the national vaccine recommendations and enable younger Australian adolescents to receive Q fever vaccine and be protected against this serious disease.”

Improving the lives of those with brain cancer

Associate Professor Haryana Dhillon (pictured right) will lead a $4.97m comprehensive research program to improve the lives of people with brain cancers and their families.

The program of work includes ongoing assessment of a patient and caregiver needs, from referral to treatment, rehabilitation, and community support, to systematically identify and intervene in areas of need.

Professor Dhillon and her team will also create a national repository of information resources, a national care coordination service and develop and roll out interventions to address gaps in care, including a collaboration with CanTeen to support young adult brain cancer survivors to re-engage with life.

“Our program of work recognises the complex and varied needs of people with brain cancer. Our collaboration brings together clinicians, researchers, and four cooperative cancer trials groups with the aim of personalising care and support for these people and their families.

“Our innovative approach taking services and support to where people need them, through tele-health, web-based interventions and improved linkage to local services, will help to overcome inequities of distance and limited healthcare services in rural and remote Australia.”

All awarded projects

Associate Professor Haryana Dhillon

Brain cancer survivorship grant

Brain cancer rehabilitation, assessment, intervention of survivor needs

$4,973,026

Associate Professor Nicholas Wood

Clinical trials activity – Rare cancers, rare diseases and unmet need grant

Optimising Q fever vaccination in Australia: Protecting our rural adolescents

$1,772,624

Professor Allison Tong

Clinical trials activity – Rare cancers, rare diseases and unmet need grant

Structured exercise program to reduce fatigue in patients receiving dialysis: a preference-stratified adaptive trial

$1,957,499

Professor Mark Dadds

Clinical trials activity – neurological disorders grant

Evaluation of a new brief intervention for childhood autism spectrum disorders

$837,447

Dr Rhonda Farrell

Clinical trials activity – Reproductive cancers grant

A randomised pilot study comparing chemotherapy treatments for stage 3 epithelial ovarian, fallopian tube and primary peritoneal cancer

$686,674

Professor Linda Milehskin

Clinical trials activity – Reproductive cancers grant

Treatments for pelvic chemoradiation in high risk endometrial cancer

$1,633,241

Associate Professor Chee Khoon Lee

Clinical trials activity – Reproductive cancers grant

Treatments for women with hormone receptor positive recurrent/metastatic gynaecological neoplasms

$1,995,422

Professor Nehmat Houssami

Preventive and public health research initiative – Targeted health system and community organisation grant

Evidence on the clinical effectiveness and cost-effectiveness of digital breast tomosynthesis in identifying breast cancer compared to standard imaging in populations at risk of breast cancer

$1,422,683

Associate Professor Hasantha Gunasekera

Indigenous health grant

Aboriginal community controlled ear health support system: developing, embedding and evaluating best practice models of care

$1,422,683

Professor David Celermajer

Improving health outcomes in congenital heart disease for young adults, their families and the health system

$750,000

Professor Stuart Grieve

Enabling precision medicine by “deep phenotyping” cardiovascular disease with imaging

$750,000

Professor Phillip Hogg

Redefining protein function in thrombosis: Implications for pro-thrombotic states and anti-thrombotic drug resistance in patients with cardiovascular disease

$750,000

Professor Shaun Jackson

Investigation of a new prothrombotic mechanism linking diabetes to cardiovascular disease

$750,000

Associate Professor Simone Schoenwaelder

Towards the development of safer anticoagulants for the treatment of stroke

$750,000

Associate Professor Steven Wise

Establishing a centre for pre-clinical evaluation of cardiovascular devices

$750,000

Dr Paul Coleman

Redox control of VWF processing and activity during thrombotic diseases

$450,000

Dr Kristina Cook

Starving for oxygen: The role of hypoxia inducible factor in the development of heart failure

$450,000

Dr Karice Hyun

eGuardian Angel: Interactive peer support based on the concept of emotional contagion

$450,000

Associate Professor Eddy Kizana

Overcoming the barrier to human cardiac gene therapy

$450,000

Associate Professor Saurabh Kumar

Standard care or a rapid early invasive management approach to patients with life-threatening heart rhythm disorders

$450,000

Dr Renjing Liu

Targeting Tet2 as a therapy for vascular calcification

$450,000

Associate Professor Ricky O’Brien

Developing radiation-ablation techniques to treat ventricular tachycardia and atrial fibrillation

$450,000

Dr Stephanie Partridge

Preventing obesity in adolescents using a co-designed and interactive text message program

$450,000

Dr Freda Passam

Targets for the prevention of cardiovascular thrombosis in metabolic syndrome

$450,000

Associate Professor Sanjay Patel

Colchicine cardiovascular outcomes in acute Coronary syndrome study

$450,000

Dr Faraz Pathan

The impact of obesity on cardiovascular hemodynamics – a life span study

$450,000

Dr Yanfei (Jacob) Qi

Targeting blood vessel cells to treat atherosclerosis

$450,000

Dr Pierre Qian

Microwave ablation system for treating hypertension

$450,000

/University Release. The material in this public release comes from the originating organization and may be of a point-in-time nature, edited for clarity, style and length. View in full here.